gms | German Medical Science

72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

06.06. - 09.06.2021

Artikel

Artikel empfehlen

Extent and prognostic relevance of MGMT promotor methylation does not differ between glioblastoma and IDH-wildtype TERT-mutated astrocytoma

Ausmaß und prognostische Relevanz der MGMT Promotor Methylierung unterscheidet sich nicht zwischen Glioblastomen und IDH-Wildtyp TERT mutierten Astrozytomen

Meeting Abstract

Suche in Medline nach

  • presenting/speaker Nico Teske - Ludwig-Maximilians-University School of Medicine, Department of Neurosurgery, München, Deutschland; German Cancer Consortium (DKTK), Partner Site Munich, München, Deutschland
  • Philipp Karschnia - Ludwig-Maximilians-University School of Medicine, Department of Neurosurgery, München, Deutschland; German Cancer Consortium (DKTK), Partner Site Munich, München, Deutschland
  • Jonathan Weller - Ludwig-Maximilians-University School of Medicine, Department of Neurosurgery, München, Deutschland; German Cancer Consortium (DKTK), Partner Site Munich, München, Deutschland
  • Sebastian Siller - Ludwig-Maximilians-University School of Medicine, Department of Neurosurgery, München, Deutschland; German Cancer Consortium (DKTK), Partner Site Munich, München, Deutschland
  • Mario M. Dorostkar - German Cancer Consortium (DKTK), Partner Site Munich, München, Deutschland; Ludwig-Maximilians-University School of Medicine, Center for Neuropathology and Prion Research, München, Deutschland
  • Jochen Herms - German Cancer Consortium (DKTK), Partner Site Munich, München, Deutschland; Ludwig-Maximilians-University School of Medicine, Center for Neuropathology and Prion Research, München, Deutschland
  • Louisa von Baumgarten - Ludwig-Maximilians-University School of Medicine, Department of Neurosurgery, München, Deutschland; German Cancer Consortium (DKTK), Partner Site Munich, München, Deutschland
  • Jörg-Christian Tonn - Ludwig-Maximilians-University School of Medicine, Department of Neurosurgery, München, Deutschland; German Cancer Consortium (DKTK), Partner Site Munich, München, Deutschland
  • Niklas Thon - Ludwig-Maximilians-University School of Medicine, Department of Neurosurgery, München, Deutschland; German Cancer Consortium (DKTK), Partner Site Munich, München, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie. sine loco [digital], 06.-09.06.2021. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocP076

doi: 10.3205/21dgnc364, urn:nbn:de:0183-21dgnc3643

Veröffentlicht: 4. Juni 2021

© 2021 Teske et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

Objective: The cIMPACT-NOW update 6 introduced glioblastoma diagnosis based on the combination of IDH-wildtype status and TERT promotor mutation. MGMT promotor methylation is associated with outcome in glioblastoma as defined by histopathology according to the WHO 2016 classification. However, it is yet unclear whether this is also valid in molecularly defined glioblastoma.

Methods: We searched the institutional database for patients with: 1.) glioblastoma defined by histopathology; and 2.) IDH-wildtype astrocytoma with TERT promotor mutation. MGMT promotor methylation was analysed using methylation-specific PCR and Sanger sequencing of CpG sites within the MGMT promotor region.

Results: We identified 224 patients with glioblastoma diagnosed based on histopathology, and 71 patients with IDH-wildtype, TERT-mutated astrocytoma including 32 WHO°II and 39 WHO°III astrocytomas. There was no difference in the number of MGMT methylated tumors between the two groups as determined per PCR, and also neither the number nor the pattern of methylated CpG sites differed as determined per Sanger sequencing. Progression-free (PFS) and overall survival (OS) was similar between the two groups (glioblastoma vs IDH-wildtype, TERT-mutated astrocytoma; PFS 9 vs 8 months, p=0.191; OS 18 vs 22 months, p=0.655). In both glioblastoma and IDH-wildtype TERT-mutated astrocytoma higher numbers of methylated CpG sites were associated with prolonged radiographic progression free survival.

Conclusion: Extent of MGMT promotor methylation and its clinical impact is similar in both histopathological glioblastoma and IDH-wildtype, TERT-mutated astrocytoma. Our data appear to support the role of MGMT promotor methylation also in molecularly defined glioblastoma according to the cIMPACT-NOW update 6.

Figure 1 [Fig. 1], Figure 2 [Fig. 2]